Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
31-45 of 2288 results
FDA approves DARZALEX for relapsed multiple myeloma
Genmab has secured approval from the US Food and Drug Administration (FDA) to use DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug Research > Drug Delivery > News
Immune Pharmaceuticals secures up to $11m in new financing
Immune Pharmaceuticals has secured up to $11m in new financing, which will be deployed with a focus on bertilimumab clinical development.
Drug Research > Drug Delivery > News
Albireo’s lead product candidate for PFIC accepted into EMA's PRIME Program
Albireo Pharma's lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) to treat progressive familial intrahepatic cholestasis (PFIC).
Drug Research > Drug Delivery > News
Midatech Pharma selects MTR104 candidate for liver cancer treatment
Midatech Pharma has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018.
Drug Research > Drug Delivery > News
Pfizer’s Celebrex found to be no riskier for hearts than other rival pain drugs
By PBR Staff Writer
A new study has found that Pfizer’s arthritis drug Celebrex (celecoxib) posed no higher risk to a patient’s heart when compared to its rivals, Ibuprofen and Naproxen.
Drug Research > Drug Delivery > News
Amgen partners with Janssen to co-fund studies with KYPROLIS and DARZALEX in multiple myeloma
Amgen and Janssen Pharmaceuticals are collaborating in multiple clinical trials assessing the combination of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in patients with multiple myeloma (MM).
Drug Research > Drug Delivery > News
Therapix completes formulation development for tablet for sublingual administration of pharmaceutical use
Therapix Biosciences has completed the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use.
Drug Research > Drug Delivery > News
EC grants orphan drug designation to Philogen's soft tissue sarcoma treatment
Philogen has secured Orphan Drug Designation from the European Commission (EC) to L19TNF - a non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format - for the treatment of soft-tissue sarcoma.
Drug Research > Drug Delivery > News
La Jolla receives positive opinion from European Orphan Committee for LJPC-401 in SCD
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending La Jolla Pharmaceutical's LJPC-401 (synthetic human hepcidin) for designation as an orphan medicinal product for the treatment of Sickle Cell Disease (SCD).
Drug Research > Drug Delivery > News
Vanda settles Fanapt patent litigation with Taro
Vanda Pharmaceuticals has settled Fanapt patent litigation with Taro Pharmaceuticals.
Drug Research > Drug Delivery > News
Clinigen expands operations into Japan
Pharmaceuticals and services group Clinigen Group has opened an office in Tokyo from which it will run its newly-launched Japanese business.
Drug Research > Drug Delivery > News
Pfizer plans to launch REMICADE biosimilar in US in November
Pfizer said it will begin shipping INFLECTRA (infliximab-dyyb)for injection, a biosimilar of REMICADE (infliximab) to wholesalers in the US in late November 2016.
Drug Research > Drug Delivery > News
TFS buys dermatology specialist SCIderm
TFS has acquired German dermatology specialist SCIderm.
Drug Research > Drug Delivery > News
NICE recommends AstraZeneca's osimertinib drug for people with lung cancer
The UK's National Institute for Health and Care Excellence (NICE) said that AstraZeneca's osimertinib drug, also known as Tagrisso, should be made available on the Cancer Drugs Fund (CDF).
Drug Research > Drug Delivery > News
PAREXEL agrees to acquire ExecuPharm
PAREXEL International has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry.
Drug Research > Drug Delivery > News
31-45 of 2288 results